XyloCor Therapeutics
PrivateLast Round
Series B
Jan 7, 2025
Est. Valuation
$130M
Total Funding Raised
$107.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
XyloCor Therapeutics is a biotechnology company developing gene therapies for patients with advanced coronary artery disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
XyloCor Therapeutics Comparables
Compare XyloCor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gene Biotherapeutics Inc. | 80% | |
| Medera | 77% | |
| Nuevocor | 77% |
XyloCor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 7, 2025 | ||||
| Series A Extension | Mar 22, 2021 | ||||
| Series A | Dec 6, 2018 |
XyloCor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A Extension, Series B, Series A |
| Fountain Healthcare Partners | Series B, Series A Extension |
| EQT AB | Series B |
| Lumira Ventures | Series A Extension, Series B |
| Longwood Fund | Series A Extension |
| Jeito Capital | Series B |
| Sofinnova Investments | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 30, 2026
Grew 18% QoQ from 17 to 20 employees.
- Aug 21, 2026
Monthly visitors increased 37% MoM.
XyloCor Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about XyloCor Therapeutics's valuation, stock price, and market status.
Is XyloCor Therapeutics a public or private company?
XyloCor Therapeutics is a private company.
What is the current stock price of XyloCor Therapeutics?
XyloCor Therapeutics is a private company, so its shares have no public market price. Caplight tracks XyloCor Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is XyloCor Therapeutics worth (valuation)?
XyloCor Therapeutics's valuation is estimated at $130.0M based on funding round data.
Can I buy XyloCor Therapeutics stock?
XyloCor Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was XyloCor Therapeutics's last funding round?
XyloCor Therapeutics's most recent funding round was Series B on January 7, 2025.
Who are the main investors in XyloCor Therapeutics?
Key investors in XyloCor Therapeutics include EQT Life Sciences, Fountain Healthcare Partners, Jeito Capital, Sofinnova Investments.
Will XyloCor Therapeutics IPO soon?
No public IPO plans have been announced for XyloCor Therapeutics.
How can I track XyloCor Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in XyloCor Therapeutics's shares on secondary markets.